Efficacy and safety of entecavir on HBeAg positive chronic active hepatitis B

Abstract

Objective To study the effect and safety of entecavir on HBeAg positive hepatitis B virus (HBV) infection. Methods A total of 120 patients with HBeAg positive HBV were selected as research objects, and were randomly divided into study group and control group. Patients in study group were treated with entecavir, patients in control group were treated with adefovir dipivoxil. Results The negative conversion rate of HBV-DNA in study group was significantly higher than that in control group at every stage of treatment (P<0.05). After 12, 24 and 48 weeks of treatment, the HBeAg conversion rate in study group was significantly higher than that in control group (all P<0.05). The liver improvement of the patients in study group were significantly superior to those in control group at ever stage of treatment (P<0.05). The incidence of adverse reactions of study group was significantly lower than that of control group (P<0.05). Conclusions Entecavir antiviral therapy for HBeAg positive chronic active HBV can effectively improve the therapeutic effect, which is superior to adefovir dipivoxil. It is worthy of promotion and application clinically. Key words: Entecavir; Adefovir dipivoxil; Hepatitis B virus; Clinical observation; Security